Edwards LifesciencesEWEarnings & Financial Report
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
EW Q1 FY2026 Key Financial Metrics
Revenue
$1.6B
Gross Profit
$1.3B
Operating Profit
$29.0M
Net Profit
$380.7M
Gross Margin
78.0%
Operating Margin
1.8%
Net Margin
23.1%
YoY Growth
16.7%
EPS
$0.66
Edwards Lifesciences Q1 FY2026 Financial Summary
Edwards Lifesciences reported revenue of $1.6B (up 16.7% YoY) for Q1 FY2026, with a net profit of $380.7M (up 6.8% YoY) (23.1% margin). Cost of goods sold was $362.6M, operating expenses totaled $1.3B.
Key Financial Metrics
| Total Revenue | $1.6B |
|---|---|
| Net Profit | $380.7M |
| Gross Margin | 78.0% |
| Operating Margin | 1.8% |
| Report Period | Q1 FY2026 |
Edwards Lifesciences Annual Revenue by Year
Edwards Lifesciences annual revenue history includes year-by-year totals (for example, 2025 revenue was $6.1B).
Edwards Lifesciences Quarterly Revenue & Net Profit History
Edwards Lifesciences results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $1.6B | +16.7% | $380.7M | 23.1% |
| Q4 FY2025 | $1.6B | +13.3% | $91.2M | 5.8% |
| Q3 FY2025 | $1.6B | +14.7% | $291.1M | 18.7% |
| Q2 FY2025 | $1.5B | +11.9% | $333.2M | 21.7% |
| Q1 FY2025 | $1.4B | +6.2% | $358.0M | 25.3% |
| Q4 FY2024 | $1.4B | +9.4% | $385.6M | 27.8% |
| Q3 FY2024 | $1.4B | +8.9% | $3.1B | 226.7% |
| Q2 FY2024 | $1.4B | +7.1% | $366.3M | 26.7% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.37B | $1.35B | $1.39B | $1.41B | $1.53B | $1.55B | $1.57B | $1.65B |
| YoY Growth | 7.1% | 8.9% | 9.4% | 6.2% | 11.9% | 14.7% | 13.3% | 16.7% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.10B | $12.97B | $13.06B | $13.02B | $13.49B | $13.27B | $13.70B | N/A |
| Liabilities | $2.59B | $3.36B | $2.99B | $2.83B | $2.88B | $3.07B | $3.36B | N/A |
| Equity | $7.44B | $9.55B | $10.00B | $10.13B | $10.55B | $10.21B | $10.34B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $371.5M | $351.8M | $-127.5M | $280.4M | $290.2M | $573.7M | $450.9M |